Miyoko Christina Yi - 08 Dec 2022 Form 4 Insider Report for Provention Bio, Inc.

Role
Chief Operations Officer
Signature
/s/ Thierry Chauche, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
08 Dec 2022
Net transactions value
$0
Form type
4
Filing time
09 Dec 2022, 19:36:57 UTC
Previous filing
23 Nov 2022
Next filing
11 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRVB Stock Option (right to buy) Award $0 +6,000 +3.1% $0.000000 201,000 08 Dec 2022 Common Stock, par value $0.0001 6,000 $5.88 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As previously reported on a Form 4 filed on December 20, 2021, on December 16, 2021 the Reporting Person was granted a stock option for 300,000 shares of Common Stock, 150,000 of which option shares vest in four equal annual installments commencing on December 16, 2022 and 150,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 6,000 of the 150,000 performance option shares on December 8, 2022 upon the satisfaction of certain performance milestones.
F2 The stock options were granted pursuant to the Issuer's 2020 Inducement Plan.
F3 Represents the 150,000 time-based option shares referred to in footnote (1) plus the 6,000 vested performance option shares referred to in footnote (1) plus 45,000 vested performance shares which vested on November 22, 2022.